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Abstract 
Background: Despite recent studies on the role of ubiquitin-related SUMO modifier in cell fate decisions, our under-
standing on precise molecular mechanisms of these processes is limited. Previously, we established that the SUMO 
isopeptidase SENP3 regulates chromatin assembly of the MLL1/2 histone methyltransferase complex at distinct HOX 
genes, including the osteogenic master regulator DLX3. A comprehensive mechanism that regulates SENP3 transcrip-
tional function was not understood.
Results: Here, we identified flightless-I homolog (FLII), a member of the gelsolin family of actin-remodeling proteins, 
as a novel regulator of SENP3. We demonstrate that FLII is associated with SENP3 and the MLL1/2 complex. We further 
show that FLII determines SENP3 recruitment and MLL1/2 complex assembly on the DLX3 gene. Consequently, FLII is 
indispensible for H3K4 methylation and proper loading of active RNA polymerase II at this gene locus. Most impor-
tantly, FLII-mediated SENP3 regulation governs osteogenic differentiation of human mesenchymal stem cells.
Conclusion: Altogether, these data reveal a crucial functional interconnection of FLII with the sumoylation machin-
ery that converges on epigenetic regulation and cell fate determination.
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Background
The ubiquitin-like SUMO (small ubiquitin-like modi-
fier) system has emerged as a key regulator of cell func-
tion [1–5]. SUMO covalently modifies its target proteins 
and has important implications not only in adult life 
but also during early development [6, 7]. The multistep, 
ATP-dependent SUMO conjugation pathway requires an 
enzymatic (E1–E2–E3) cascade for the formation of an 
isopeptide bond between the carboxy-terminal di-glycine 
motif of SUMO paralogs (SUMO1 and the highly related 
SUMO2/3) and lysine residues in a target protein. The 
modification is reversed by specific cysteine proteases, 
commonly termed SUMO-specific isopeptidases or 
SUMO proteases. These enzymes cleave the isopeptide 
bond between the SUMO moiety and substrates. SUMO-
specific isopeptidases belong to three distinct families, 
viz. the Ulp/SENP, the Desi and the USPL1 family [8–10]. 
In humans, six different SENP isoforms (SENP1, 2, 3, 
5, 6 and 7) with distinct subcellular localizations, sub-
strate specificities and functions have been identified. 
For example, SENP3 exerts preferential cleavage activity 
toward SUMO2-/3-modified substrates. It is distributed 
in the nucleolus and nucleoplasm and shuttles between 
these two compartments in an mTOR-controlled process 
[11]. Work from our group and others has initially estab-
lished a role of SENP3 in ribosome maturation [11–14]. 
Subsequently, we and others could also unravel a crucial 
function of SENP3 in the control of gene expression [15–
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The coordinated expression of HOX genes that encode 
homeodomain-containing transcription factors is criti-
cal for embryonic development [19–21]. In adult tissues, 
HOX genes are involved in regulating cell commitment 
pathways such as hematopoietic differentiation [22]. The 
distal-less (Dll) family of HOX genes, which encodes DLX 
transcription factors, has a critical role in limb develop-
ment, brain patterning and craniofacial morphogenesis 
[23]. DLX3 exerts key functions in osteogenic differen-
tiation, and accordingly loss of DLX3 expression is a sig-
nature of defective osteogenic differentiation processes 
[24–27].
The expression of HOX genes is exquisitely regulated 
by the epigenetic modifiers, trithorax (trxG)- and Poly-
comb (PcG)-group proteins, which activate or repress 
HOX genes, respectively [28–32]. The mixed lineage leu-
kemia (MLL)–histone methyltransferase (HMT) complex 
proteins belong to the trxG group and catalyze trimeth-
ylation of lysine 4 on histone 3 (H3K4me3) [33, 34]. This 
is typically associated with an active state of chroma-
tin and thus found on transcriptionally active genes or 
developmentally regulated bivalent promoters [35–40]. 
In mammals, distinct subtypes of MLL complexes are 
found. They all consist of a SET1/MLL methyltransferase 
(SET1A/B, MLL1, 2, 3 or 4) as the catalytic core [41–43]. 
However, for optimum catalytic activity the core requires 
the association with a multiprotein module minimally 
composed of WDR5, RbBP5, Ash2L and DPY-30, known 
as WRAD module [44]. The ordered and timed assembly 
of the WRAD module at chromatin is one critical point 
in the control of SET1/MLL function [41, 45]. Our ear-
lier work established a SUMO-dependent mechanism 
of this assembly process at a subset of HOX genes. We 
had shown that the MLL1/2 complex subunit RbBP5 is 
covalently modified by SUMO2. We further demon-
strated that the SUMO isopeptidase SENP3 catalyzes the 
desumoylation of RbBP5, which is a prerequisite for the 
recruitment of Ash2L and menin into functional MLL1/2 
complexes at a subset of HOX genes, including the DLX3 
gene [18]. However, how SENP3 itself is regulated and 
targeted to perform its transcription regulatory role 
remained unclear.
Here, we identify flightless-I homolog (FLII) as a 
central player in this process. FLII has initially been 
described as an actin-remodeling protein that belongs to 
the evolutionary conserved gelsolin protein superfam-
ily [46–48]. The FLII protein consists of an N-terminal 
leucine-rich repeat (LRR) domain involved in protein–
protein interaction. The C-terminus of FLII is made up 
of the gelsolin-like domain, which mediates actin binding 
and protein–protein interaction. FLII function has been 
assigned to cytoskeleton organization during cell migra-
tion and negative regulation of wound repair [49]. Apart 
from cytoskeleton-related functions, FLII has also been 
shown to act as a transcriptional co-activator in nuclear 
receptor signaling [50].
In this study, we identify FLII as a major regulator of 
SENP3. We demonstrate that FLII regulates the chroma-
tin association of SENP3, thereby modulating MLL1/2 
complex activity. Through this pathway, FLII governs 
DLX3 gene expression and determines osteogenic differ-
entiation process of human mesenchymal stem cells.
Result
FLII is a major interactor of SENP3
Our earlier work unraveled a functional and physi-
cal association of SENP3 with pre-60S ribosomes and 
MLL1/2 histone methyltransferase complexes [13, 14, 
18]. A major interaction platform for SENP3 at pre-60S 
ribosomes is the PELP1 complex, but how SENP3 is 
targeted to chromatin and the MLL1/2 complex is cur-
rently unknown. In order to investigate these issues, we 
performed a system-wide interactome study for endog-
enous SENP3 using SILAC (stable isotope labeling in cell 
culture)-based mass spectrometry (MS). Cell lysates from 
HeLa cells labeled with light or heavy amino acids were 
incubated with either control or anti-SENP3 antibodies 
for immunoprecipitation. Following separation by SDS-
PAGE, proteins were excised from gels, trypsinized and 
peptides measured by MS. After applying a number of 
stringent filtering criteria (as detailed in the legends to 
Additional file  1: Figs. S1 and S2), a cytoscape (version 
3.3.0) map of the SENP3 interactome was generated. The 
map is comprised of 27 proteins that satisfied multilay-
ered filtering criteria. Among the SENP3-associated pro-
teins with the highest SILAC ratio, highest peptide count 
and lowest PEP score, we consistently found FLII (Addi-
tional file 1: Fig. S1, Additional file 2: Table S1).
When these 27 high-confident proteins were analyzed 
in STRING database [51], a high clustering coefficient 
of 0.863 was observed (Additional file  1: Fig. S2). This 
indicates that the proteins enriched by SENP3 IP are 
high probability clusters of functionally related protein 
groups. Accordingly, when the SENP3 cytoscape clus-
ter was integrated in the known FLII network extracted 
from STRING database (version 10.0), we found another 
FLII interacting protein LRRFIP1 as a common high con-
fidence candidate identified in the SENP3 interactome 
(Additional file  1: Fig. S2b). This further indicates that 
SENP3 is connected to FLII.
To validate the MS data, directed co-immunopre-
cipitation assays were performed. To this end, we first 
expressed a Flag-tagged SENP3 version in HeLa cells by 
transient transfection and performed anti-Flag IPs. In 
this setup, endogenous FLII was specifically captured 
on anti-Flag beads (Additional file  1: Fig. S3a). When 
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immunoprecipitating endogenous SENP3, we detected 
the known SENP3 interactors PELP1 and LAS1L upon 
immunoblotting with the respective antibodies. More-
over, we strongly enriched for endogenous FLII and 
LRRFIP1 in the anti-SENP3 IP, but not in the IgG control 
IP (Fig. 1a). Notably, upon depletion of SENP3 by siRNA, 
FLII was lost in the anti-SENP3 IPs, ruling out that the 
SENP3–FLII co-IP results from an antibody cross-
reaction (Fig.  1b). Moreover, in a reverse anti-FLII-IP, 
endogenous SENP3 as well as LRRFIP1 was detected by 
immunoblotting with the respective antibodies (Fig. 1c).
To probe for direct interaction between FLII and 
SENP3 and to map the binding domain of SENP3 in 
FLII, we performed GST pull-down assays using recom-
binantly expressed fragments of FLII. The LRR, GelA and 
GelB domains were fused to GST and used as baits in 
pull-down assays to test for binding to SENP3, which was 
generated by in  vitro transcription/translation in a rab-
bit reticulocyte-based system (Fig.  1d). The experiment 
revealed a physical interaction of SENP3 predominantly 
with the GelA domain of FLII.
Previous reports have described both nuclear and cyto-
solic localizations of FLII [47, 48, 52]. To see in which 
compartment the SENP3–FLII interaction occurs, cel-
lular proteins were separated in a nuclear and cytosolic 
fraction and IPs were performed. Anti-FLII immunopre-
cipitation from the different fractions indicates that the 
FLII–SENP3 interaction is mostly nuclear (Additional 
file 1: Fig. S3b). In accordance with this, immunofluores-
cence assays revealed the distribution of both proteins 
in the nucleoplasm (Additional file  1: Fig. S3c). Taken 
together, these observations establish a robust and spe-
cific nuclear interaction of SENP3 with FLII via its GelA 
domain.
FLII is involved in the regulation of SENP3‑controlled DLX3 
gene expression
Next, we addressed the physiological relevance of FLII 
binding to SENP3. Because we had defined DLX3 as a 
SENP3-regulated gene, DLX3 expression was chosen 
as a model system [18]. We initially monitored DLX3 
mRNA levels by RT-qPCR in control cells or in cells 
Fig. 1 FLII is a major novel interactor of SENP3. a Immunoprecipitation using anti-SENP3 antibody was performed on extracts from HeLa cells. 
Immunoprecipitates were analyzed by SDS-PAGE and probed with antibodies as indicated. b Similar to a except, SENP3 was depleted from HeLa 
cells by siRNA. After 72 h of siRNA transfection, SENP3 IP was performed. SDS-PAGE and immunoblotting with selected antibodies were performed 
as indicated. c Same as b but antibody directed against FLII was used for immunoprecipitation. d Schematic representation of FLII domain structure. 
The numbers in brackets indicate the amino acids. Equal amounts of in vitro transcribed/translated SENP3 were mixed with either GST only as a 
control or with GST-tagged FLII fragments (GST-LRR, GST-GelA and GST-GelB) and GST pull-down was performed. After intensive washing, bound 
proteins were eluted in SDS-sample buffer, separated by SDS-PAGE and probed for the presence of SENP3
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depleted from FLII by two different siRNAs. Intrigu-
ingly, when compared to controls, depletion of FLII 
with either siRNA results in a fivefold–tenfold down-
regulation of DLX3 mRNA expression (Fig. 2a). Expres-
sion of the siRNA-resistant Gel A or GelA/B domains of 
FLII restores the DLX3 gene expression to nearly 65 and 
80%, respectively (Fig.  2b). Notably, FLII protein deple-
tion had almost no effect on expression of the home-
obox gene HOXC8 (Fig.  2a), which is also not sensitive 
to SENP3 depletion [18]. To get a first clue whether FLII 
and SENP3 dictate DLX3 expression via a common path-
way, we co-depleted both proteins by siRNA. Impor-
tantly, when compared to individual depletion of either 
SENP3 or FLII, co-depletion of both proteins did not fur-
ther decrease DLX3 mRNA levels indeed supporting the 
idea that SENP3 and FLII act in a common pathway in 
controlling DLX3 expression (Fig. 2c).
In our previous work, we demonstrated that SENP3 
is associated with MLL1/2 methyltransferase com-
plexes and exerts control on DLX3 expression by 
regulating the assembly of these complexes. Based 
the above physical association of SENP3 and FLII, we 
therefore asked whether FLII is also associated with 
MLL1/2 components. To address this, we performed 
endogenous anti-FLII IPs and tested for the presence 
of components of MLL1/2 complexes in the immu-
noprecipitated material. We detected RbBP5, menin, 
WDR5 and the catalytic core subunits MLL1 and 
MLL2, but not the related Set1A protein in the FLII 
immunoprecipitate (Fig. 3a; Additional file 1: Fig. S4a–
c). Moreover, by employing GST pull-down assays we 
observed a physical interaction between RbBP5 and 
FLII mediated mostly through the GelA domain (Addi-
tional file 1: Fig. S4d and e).
Fig. 2 FLII controls DLX3 gene expression. a FLII was depleted from HeLa by two independent siRNAs. Total RNA was prepared from control cells or 
cells transfected with either SENP3 or FLII siRNA. RNA was reverse transcribed and cDNA was used in real-time quantitative PCR (RT-qPCR) to moni-
tor the expression of DLX3 and HOXC8. Normalized values (against GAPDH mRNA level) represent the average of three independent experiments 
performed in triplicate ± SEM (n = 3, T test, ***p < 0.001, n.s. not significant). The lower panel demonstrates efficient depletion of SENP3 or FLII. b 
Same as in a except flag-FLII domains were expressed. Data represent the average values from three independent experiments in duplicate ± SEM. 
c Same as in a except co-depletion of FLII together with SENP3 was performed. The lower panel is a representative western blot, demonstrating 
efficient depletion of SENP3 and FLII
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To reveal a functional connection of FLII to the 
MLL1/2 methyltransferase complex, we co-depleted 
cells from FLII together with distinct components of the 
MLL1/2 complexes. Similar to what was observed upon 
co-depleting SENP3 and FLII, co-depletion of RbBP5 or 
WDR5 together with FLII did not further reduce the level 
of DLX3 mRNA when compared to their single deple-
tion (Fig.  3b). These observations support the idea of a 
common signaling pathway involving SENP3, FLII and 
MLL1/2 complexes in the execution of DLX3 expression.
Next, we asked whether FLII regulates a broader 
spectrum of HOX genes. To this end, we investigated 
the effect of FLII depletion on the expression of a set 
of selected HOX genes—HOXA9, HOXB3, MEIS1 and 
MEOX1—that were previously defined as SENP3-
responsive genes [18]. Importantly, depletion of FLII 
by two different siRNAs resulted in down-regulation of 
mRNA transcripts of all four genes (Fig. 3c) and further 
strengthened the idea that FLII is involved in regulat-
ing the expression of HOX genes in conjunction with 
SENP3.
Noteworthy, the transcriptional function of FLII has 
previously connected to the estrogen receptorα (ERα) 
pathway (50). However, since ERα is not expressed in 
HeLa cells, the effects described here cannot be assigned 
to an interplay of FLII with ERα. Moreover, in the ERα-
positive MCF7 cell line, SENP3 does not act in con-
junction with FLII in ERα-mediated gene regulation 
(Additional file 1: Fig. S5a).
SENP3 recruitment to its target gene DLX3 is dependent 
on FLII
We next aimed to determine the molecular mechanism 
of FLII-controlled SENP3 function. As the catalytic activ-
ity of SENP3 is indispensible for DLX3 gene expression, 
we first checked whether FLII has any role in modulating 
SENP3 catalytic activity. However, a SENP3 activity assay 
in HeLa cell lysates from control cells or cells depleted 
from FLII did not reveal differences in catalytic activity 
(Additional file 1: Fig. S5b and c).
We next focused on a possible direct role of FLII at 
chromatin and therefore asked whether FLII is present 
Fig. 3 FLII is functionally associated with MLL1/2 complexes and governs HOX gene expression. a Endogenous FLII was immunoprecipitated from 
HeLa cell extracts, and the immunoprecipitates were probed for the presence of RbBP5, menin, MLL1 or MLL2 as indicated. b Same as Fig. 2a except 
total RNA was prepared from control cells or cells individually depleted for FLII, RbBP5 and WDR5 (SET1/MLL component subunit) by siRNAs or 
co-depleted for FLII and the indicated SET1/MLL components. RNA was reverse transcribed and cDNA was used in RT-qPCR to monitor DLX3 gene 
expression. Data represent as the average of three independent experiments performed in triplicate ± SEM. c FLII was depleted from HeLa by two 
independent siRNAs, and RT-qPCR was performed to monitor the expression of HOXA9, HOXB3, MEIS1 and MEOX1 (n = 3, T test, *p < 0.05; **p < 0.01; 
***p < 0.001, n.s. not significant)
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at the DLX3 gene. To address this issue, ChIP (chromatin 
immunoprecipitation) assays were performed in order to 
monitor the binding of SENP3 and FLII in the promoter 
region or exon 3 of DLX3 gene as we had previously 
detected SENP3 at these sites (Fig. 4a) [18]. Cross-linked 
chromatin–protein complexes from HeLa cells indeed 
revealed a strong enrichment of exogenous Flag-tagged 
FLII as well as endogenous FLII on the DLX3 gene locus 
(Additional file 1: Fig. S6a; Fig. 4b). Importantly, enrich-
ment of FLII on chromatin was not influenced by deple-
tion of SENP3 (Fig. 4b), indicating that FLII was recruited 
to chromatin independently from SENP3. These results 
led us to the idea that FLII may in turn target SENP3 to 
chromatin and in particular to the DLX3 gene locus. To 
test this idea, ChIP assays with an anti-SENP3 antibody 
were performed as above, and immunopurified DLX3 
gene fragments were quantified by qPCR. Importantly, 
depletion of FLII leads to a more than threefold reduc-
tion of SENP3 at the DLX3 gene locus, both in the pro-
moter and in the exon regions (Fig. 4c). Noteworthy, this 
reduction was not due to an altered stability or expres-
sion of SENP3, as SENP3 levels remained unchanged 
upon FLII depletion (Fig. 4d; Additional file 1: Fig. S6b). 
As SENP3 is required for proper chromatin recruitment 
Fig. 4 FLII controls SENP3 targeting to the DLX3 gene and regulates MLL1/2 complex assembly. a Schematic representation of the human DLX3 
locus is shown with transcription start site marked as arrow and exons as red boxes. Primer pairs (DLX3.1 and DLX3.2) covering promoter or exon 3 
region are indicated by color lines. b Chromatin was isolated from control HeLa cells or cells depleted from SENP3 and FLII, and ChIP assays were 
performed with anti-FLII antibodies. Primer pairs DLX3.1 and DLX3.2 were used to amplify DNA recovered from immunoprecipitated chromatin. 
Values are the average of three independent experiments performed in triplicate ± SEM (T test, **p < 0.01; ***p < 0.001, n.s. not significant). c Same 
as b except SENP3 antibody was used for ChIP. d HeLa cell lysate was probed with indicated antibodies to monitor the depletion of FLII and SENP3. 
e Same as c, except anti-Ash2L and anti-RbBP5 antibodies were used in ChIP. f Same as c, except anti-H3K4me3 antibody was used for ChIP and 
GAPDH primer was included in the qPCR as a control. g Same as f, except anti-ser2 (phospho) RNA Pol II antibody was used for ChIP
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of Ash2L and menin [18], we wondered whether defec-
tive chromatin residency of SENP3 in the absence of FLII 
might also affect MLL1/2 complex assembly. Therefore, 
we followed the chromatin association of Ash2L on the 
DLX3 gene by ChIP as described above. Importantly, 
FLII depletion perfectly phenocopied the loss of SENP3 
with respect to Ash2L residency at the DLX3 gene. Very 
similar to what was observed upon depletion of SENP3, 
Ash2L occupancy at the DLX3 promoter is reduced to 
20–30%. However, RbBP5, another core subunit of the 
MLL1/2 complexes, as well as MLL1 and MLL2 itself 
remains associated with the DLX3 gene in the absence 
of either FLII or SENP3 (Fig.  4e; Additional file  1: Fig. 
S6c–e). Noteworthy, FLII depletion did not affect the 
protein level of any of the core components of MLL1/2 
complexes, ruling out that the reduced chromatin occu-
pancy in the absence of FLL is due to changes in protein 
stability (Additional file 1: Fig. S7a, b). Importantly, FLII 
depletion had no effect on Ash2L chromatin association 
at the HOXC8 gene, which is consistent with the observa-
tion that expression of HOXC8 was not sensitive to either 
FLII or SENP3 depletion (Additional file  1: Fig. S7c). 
Altogether, this indicates that FLII is involved in proper 
SENP3 targeting to distinct HOX genes, thereby control-
ling the assembly and function of MLL1/2 complexes.
To further validate this idea, we monitored H3K4 tri-
methylation (H3K4me3) at the DLX3 gene, because this 
epigenetic mark is catalyzed by MLL1/2 complexes. 
H3K4me3 can be assayed by ChIP experiments using 
an antibody directed against this modification. In FLII-
depleted cells, H3K4me3 marks at the DLX3 gene were 
reduced to 30–40%, when compared to control cells. It 
is worth noting that no reduction of H3K4 trimethyla-
tion was detected on the unrelated control gene GAPDH 
(Fig. 4f ) or HOXC8 (Additional file 1: Fig. S7d). H3K4me3 
is typically considered as a chromatin mark for active 
genes, and accordingly active RNA Pol II is found on 
genes that harbor H3K4-trimethyl marks. In particular, 
the serine 2 phosphorylated form of RNA Pol II C-ter-
minal domain (CTD) is a signature of productive tran-
scription, and it overlaps with H3K4-trimethyl-enriched 
chromatin domains [53]. We therefore monitored the 
presence of ser2P-RNA Pol II at the DLX3 gene locus in 
the presence or absence of FLII. Again, we observed more 
than twofold reduction of Pol II residency at the DLX3 
gene, but not on the control GAPDH or HOXC8 gene, 
when endogenous FLII is knocked down (Fig. 4g; Addi-
tional file 1: Fig. S7e). Collectively, these data suggest that 
FLII governs chromatin association of SENP3 on specific 
HOX genes, thereby regulating MLL1/2 complex assem-
bly, which ultimately impinges on gene activation.
To further strengthen the idea that the FLII recruits 
SENP3 to the MLL complex assembly on distinct gene 
loci at chromatin, we performed FLII siRNA followed by 
immunoprecipitation of endogenous SENP3 and probed 
for co-precipitation of RbBP5 and vice versa. When com-
pared to control cells, RBBP5 is much reduced in the 
anti-SENP3 IP upon loss of FLII. Even more strikingly 
SENP3 does not co-immunoprecipitate with RbBP5 in 
the absence of FLII (Additional file  1: Fig. S7f ). Impor-
tantly, however, SENP3 depletion did not affect Ash2L 
interaction with RbBP5 further supporting our notion 
that SENP3 does not generally affect the assembly of 
MLL complexes in solution, but acts at chromatin on dis-
tinct HOX genes. (Additional file 1: Fig. S7g).
FLII regulates sumoylation of RbBP5 and is critical 
for differentiation of human dental follicle stem cells
In our previous work, we had shown that the MLL1/2 
complex subunit RbBP5 is covalently modified by 
SUMO2. We further demonstrated that SENP3 catalyzes 
the desumoylation of RbBP5, which is a prerequisite for 
the recruitment of Ash2L and menin into functional 
MLL1/2 complexes at the DLX3 gene [18]. Since FLII 
is needed for SENP3 recruitment to the DLX3 gene, we 
reasoned that loss of FLII would translate into an altered 
sumoylation status of RbBP5. To test this possibility, we 
introduced His-SUMO2 together with Flag-RbBP5 in 
HeLa cell and performed anti-Flag immunoprecipitation 
followed by anti-SUMO2/3 immunoblotting. Cells were 
either mock depleted or depleted from FLII by siRNA. 
Importantly, in anti-FLAG IPs, RbBP5–SUMO2 conju-
gates where enriched upon depletion of FLII (Fig.  5a) 
indeed suggesting that FLII is needed to channel SENP3 
activity to RbBP5.
Since loss of FLII phenocopied the loss of SENP3 with 
respect to DLX3 expression, we asked whether FLII 
is also functionally connected to osteogenic differen-
tiation. Primary human dental follicle stem cells (DFCs) 
were employed as an experimental system for the inves-
tigation of FLII function in this process. In the absence 
of SENP3, osteogenic differentiation is prevented due to 
improper induction of the DLX3, which is needed for 
the activation of downstream targets, such as RUNX2 
and alkaline phosphatase (ALP). To investigate whether 
FLII is also involved in this pathway, we depleted endog-
enous FLII from DFCs and followed the expression of 
DLX3 upon induction of differentiation. In this experi-
mental setup, loss of FLII resulted in a threefold to four-
fold reduction of DLX3 mRNA and protein levels when 
compared to control cells (Fig.  5b–d). Accordingly, the 
downstream targets of DLX3, RUNX2 and ALP were also 
down-regulated (Additional file  1: Fig. S8a). Moreover, 
a significant decrease in ALP activity (Fig.  5e), which is 
indicative of defective osteogenic differentiation, was 
observed. Proper osteogenic differentiation of DFCs 
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is characterized by intracellular deposition of calcium, 
which can be monitored by alizarin staining [54]. Impor-
tantly, FLII depletion caused drastically reduced alizarin 
staining indicating an impaired differentiation process 
(Fig.  5f and Additional file  1: Fig. S8b). Taken together, 
these findings establish a critical role of FLII in the con-
trol of osteogenic differentiation in human mesenchymal 
stem cells.
Discussion
Our previous study unraveled a pathway, in which 
SENP3-mediated desumoylation of the RbBP5 subunit 
triggers the assembly of a functional MLL1/2 complex 
by recruitment of the Ash2L and menin subunits. Here, 
we define FLII as a central regulator of this pathway and 
provide evidence that FLII determines the chromatin 
recruitment of SENP3. FLII association with SENP3 and 
MLL1/2 complex is crucial for HOX gene expression. 
Mechanistically, we could delineate that FLII action trig-
gers molecular events necessary for MLL1/2 complex 
association and subsequent epigenetic modifications per-
missive for HOX gene transcription required for human 
osteogenic differentiation.
FLII harbors an N-terminal leucine-rich repeat domain 
and two gelsolin-related domains, each of which is com-
prised of three repeats of around 150 amino acids [55]. 
Gelsolin domains define a family of actin-remodeling 
proteins, and accordingly FLII has been characterized 
as a regulator of cytoskeletal organization and actin 
dynamics. In addition to its role in actin remodeling, a 
transcriptional co-activator function in nuclear recep-
tor signaling has been assigned to FLII. FLII interacts 
Fig. 5 FLII regulates RbBP5 sumoylation and osteogenic differentiation of DFCs. a HeLa cells treated with control siRNA or FLII siRNA were trans-
fected with Flag-RbBP5 and SUMO2 as indicated, and SUMOylation of RbBP5 was monitored by anti-SUMO2 immunoblotting following anti-Flag-IP. 
The asterisk represents the sumoylated RbBP5 species. b, c Total RNA was isolated from DFCs, after treating cells with two independent FLII siRNAs 
or control siRNA. Expression of FLII (b) and DLX3 mRNA (c) was determined by RT-qPCR. Values (normalized for GAPDH expression) represent the 
mean of three experiments ± SEM. d Cell lysates originating from DFCs (b, c) were separated by SDS-PAGE and analyzed by immunoblotting with 
the indicated antibodies. e ALP activity was quantified in differentiating DFCs, 10 days after transfection with FLII siRNAs or control siRNA and 
incubation with osteogenic differentiation medium (ODM). f Mineral deposits in DFC cultures were measured by alizarin red staining after 5 weeks 
of culture with ODM and transfection with two independent FLII siRNAs or a control siRNA
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with estrogen receptor α (ERα) and the co-activators 
GRIP1 and CARM1 [50]. Moreover, FLII interacts with 
BAF53, a component of SWI/SNF chromatin remodeler 
complexes, and recruits SWI/SNF complex to its target 
genes [55]. Thus, FLII facilitates chromatin accessibil-
ity on ERα target genes, which was proposed to result 
in a proliferative advantage to breast cancer cells [56]. 
Our data are consistent with the dual roles for FLII as a 
transcriptional co-activator in the nucleus and a cyto-
plasmic modulator of the cytoskeleton. However, our 
work expands the regulatory function of FLII on tran-
scriptional processes. We provide evidence that FLII is 
physically and functionally connected to MLL1/2 histone 
methyltransferase complexes and controls the recruit-
ment of the desumoylating enzyme SENP3 to a subset of 
MLL1-/2-regulated HOX genes. Our interactome stud-
ies identified FLII as a very robust direct binding partner 
of SENP3. Binding is mediated predominantly through 
the GelA domain. Importantly, in the absence of FLII, 
SENP3 is not properly recruited to our model home-
obox gene DLX3. As a consequence of reduced SENP3 
occupancy, the MLL complex is not properly assembled, 
H3K4 trimethylation is impaired and expression of DLX3 
is down-regulated. Intriguingly, there is a striking over-
lap of HOX genes co-regulated by both FLII and SENP3. 
The expression of HOXA9, HOXB3, MEIS1, MEOX1 
and DLX3 is all affected by depletion of either FLII or 
SENP3, while HOXC8 expression remains unaltered in 
the absence of either SENP3 or FLII. Together with the 
fact that co-depletion of FLII and SENP3 is epistatic in 
controlling DLX3 expression, this strongly supports the 
idea that FLII acts on HOX gene expression through 
recruitment of SENP3. One possible scenario is that FLII, 
SENP3 and RbBP5 form a complex, in which FLII acts 
as a scaffold or adaptor that positions SENP3 in proxim-
ity to its substrate RbBP5. This allows desumoylation of 
RbBP5, which is a prerequisite for proper assembly of the 
MLL1/2 complexes at chromatin. Altogether, these data 
indicate that FLII contributes to SENP3 target selection 
by determining its recruitment to specific chromatin 
locations. How FLII acquires selectivity for addressing 
SENP3 to only a subset of MLL1/2 targets remains to be 
determined, but generally our data further strengthen the 
concept that substrate specificity of SENPs is dictated by 
spatial control. SENP3 stands as a paradigm for this con-
cept as its activity is concentrated in the nucleolus, where 
it functions in ribosome maturation in complex with 
PELP1–TEX10–WDR18, and at transcriptionally active 
chromatin sites in conjunction with SET1/MLL methyl-
transferase complexes. Our data indicate that chromatin 
association of SENP3 requires FLII, while its nucleolar 
sequestration is mainly determined by the nucleolar scaf-
fold protein nucleophosmin (NPM1) [11]. Noteworthy, 
FLII is largely excluded from the nucleolus making it 
unlikely that it is involved in the nucleolar functions of 
SENP3.
Our data also unravel an important and so far unprec-
edented implication of FLII in cell differentiation. In 
dental follicle progenitor cells, which serve as a model 
system of osteogenic differentiation, FLII depletion reca-
pitulates the loss of SENP3 and impairs expression of the 
osteogenic master regulator DLX3. This in turn affects 
the expression of osteogenic regulators, such as RUNX2 
and alkaline phosphatase, ultimately preventing proper 
osteogenesis. So far, FLII has been mainly linked to ERα-
regulated transcriptional processes. Interestingly, how-
ever, at least on some HOX genes a cross talk between 
ERα activation and MLL-dependent H3K4 trimethyla-
tion has been reported [57–60]. Based on these obser-
vations, it is tempting to speculate that the FLII–SENP3 
axis integrates multiple signaling pathways in cellular 
differentiation processes. Consistent with this idea, it 
has recently been shown that ERα regulates DLX3-medi-
ated osteoblast differentiation [61]. Generally, our work 
expands the emerging concept of actin-binding proteins 
functioning in transcriptional processes. One paradigm 
for this concept is Wave1, which has a cytoplasmic func-
tion in actin reorganization as a downstream target of 
RAC. Intriguingly, however, reminiscent to our find-
ings on FLII, nuclear Wave1, associates with SET pro-
teins and modulates their activities on HOX genes [62]. 
Understanding how the nuclear and cytosolic functions 
of actin-binding proteins are coordinated will be one key 
question for future research.
Conclusions
In summary, our work defines an unrecognized molec-
ular mechanism that connects the actin-remodeling 
protein FLII to SENP3-sensitive HOX gene regulation. 
By recruiting SENP3 to chromatin at a subset of HOX 
genes, FLII coordinates MLL complex assembly and 
recruitment of active RNA polymerase II. FLII therefore 
functions as a critical specificity factor in the control of 
SENP3-mediated gene expression programs.
Methods
Cell culture/SILAC and transfection
HeLa cells were grown using standard conditions in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum and standard antibiotics. For 
SILAC labeling, cells were cultured in DMEMs (Thermo 
Scientific, product no. 89985) supplemented with 10% 
dialyzed serum (Invitrogen), antibiotics and amino acid 
isotope (R0K0 or R6K4, Cambridge Isotope Laboratories). 
Cells were grown for five passages to ensure the incor-
poration of labeled amino acids [63]. After five passages, 
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incorporation of labeled amino acids to more than 95% 
was checked. siRNA-mediated knockdown experiments 
in HeLa cells were performed using Oligofectamine (Inv-
itrogen) according to the manufacturer’s instructions.
Mass spectrometry and data processing
Overnight in-gel trypsin (12.5  ng/μl) digested peptide 
mixture was desalted and purified by C-18 StageTip 
method. An Easy-nLCII liquid chromatography—cou-
pled to a LTQ Orbitrap Elite mass spectrometer (Thermo 
Scientific)—was used for peptide elution and mass spec 
analysis. Desalted peptide mixtures were eluted with a 
5–33% gradient HPLC solvent B (80% acetonitrile in 0.5% 
acetic acid). A mass range of m/z 150–2000 with a resolu-
tion of 120,000 was set to acquire full MS scan. Twenty 
most intense ions (Top20 method) were sequentially 
selected for CID fragmentation process. Data-dependent 
scanning mode with 90 s of dynamic inclusion was set for 
MS/MS scan. Data analysis was performed using Max-
Quant software [64] version 1.3.0.5 with supported by 
Mascot as the database search engine for peptide identifi-
cation. False discovery rate (FDR) was kept at 1% for data 
filtering, and two missed cleavages were allowed. Initial 
mass tolerance was set to 7 ppm and 0.5 Da for the frag-
ment ion level. Cysteine carbamidomethylation was set 
as fixed modification, whereas protein N-terminal acety-
lation and oxidation of methionine were defined as vari-
able modifications. Information about peptide MS/MS 
spectra was extracted from MaxQuant viewer. Cytoscape 
version 3.3.0 was used to generate protein network.
Immunoprecipitation and chromatin immunoprecipitation
Immunoprecipitations were performed as described 
[18]. For endogenous SENP3 IP-MS, 80 millions SILAC-
labeled cells were used. Cells were lysed in buffer contain-
ing 50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM EDTA, 
0.5% TritonX-100 with freshly added protease and phos-
phatase inhibitors (Complete/PhosphoSTOP, Roche). 
SENP3 IP (for 2 h) was performed with the lysate origi-
nated from R6K4, labeled cells and equal amount of R0K0 
for control rabbit IgG IP. Immune complexes were cap-
tured by proteinG dynabeads (Invitrogen) for 1 h. After 
washing, immunoprecipitates were eluted by boiling 
the beads with SDS-PAGE loading buffer. Before load-
ing in a SDS-PAGE gradient (4–20%, Biorad) gel, SENP3 
IP and control IP were mixed into 1:1 ratio. ChIP assays 
were performed according to the published method from 
[65]. After real-time PCR of ChIPed DNA, data calcula-
tion was performed by percentage of input method. Two 
percentage starting chromatin was used as input. The 
diluted input was adjusted to 100% by subtracting raw 
diluted input Cp values with 5.64. If the starting input 
fraction is 2%, then a dilution factor of 50 is 5.64 cycles 
(i.e., log2 of 50 is 5.64). Finally, the percentage of input 
was derived from the following formula, i.e., 100 × 2^(Cp 
of adjusted input − Cp (ChIP replicates)). The average of 
at least three technical replicate was considered for a par-
ticular experimental setup. Unperturbed condition (such 
as control siRNA) was set as 100. Changes in chroma-
tin occupancy were then calculated relative to 100. Data 
were presented as an average of three biological repli-
cates (unless mentioned otherwise in the corresponding 
legend) with  ±  SEM. Details of western blot and ChIP 
antibodies are described in Supplemental information.
In vitro transcription/translation and GST pull‑down assay
One microgram of pCI vector encoding the respective 
proteins was translated with the TNT T7 quick-coupled 
transcription/translation system (catalog no. L1170) from 
Promega. GST-fused FLII domains were purification, and 
GST pull-downs were performed as described previously 
[66].
Osteogenic differentiation of DFCs and measurement 
of alkaline phosphatase activity
Isolation, differentiation of DFC, siRNA-mediated pro-
tein knockdown and alkaline phosphatase assays were 
performed as described [18, 24, 54, 67, 68].
For the preparation of human dental follicle cells 
(DFCs), impacted human third molars were surgically 
removed and collected from patients with informed con-
sent. DFCs were isolated as described [18, 54]. Differenti-
ation of DFCs, siRNA-mediated protein knockdown and 
alkaline phosphatase assays were performed according to 
Nayak et al. [18].
Alizarin red staining
Long-term cultures (after 5 weeks) were washed in PBS 
and fixed with 4% formaldehyde/0.1  M PBS. Calcium 
deposits were detected by treatment with a 2% aliza-
rin red S solution (Morphisto). For quantitative meas-
urement, the alizarin red staining was solved in a 10% 
cetylpyridinium chloride monohydrate solution (PBS) for 
30 min. The optical density of samples was measured in a 
plate reader at 540 nm.
Quantitative reverse transcription polymerase chain 
reaction (RT‑qPCR)
For total RNA isolation, high-pure RNA isolation kit 
(Roche) was used. Five hundred nanograms of that was 
used for cDNA synthesis (Transcriptor First strand 
cDNA synthesis kit, Roche) by using oligo dT primer. 
RT-qPCR was performed with Fast Start DNA Master 
SYBR® Green I kit (Roche) and the Light Cycler PCR 
System (LightCycler 480 II, Roche). For normalization, 
GAPDH gene expression was used as a control gene 
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expression marker. Quantification of mRNA expression 
was performed with the standard curve method.
SENP3 catalytic activity assay
About 10 million HeLa cells (Control siRNA in parallel 
with FLII siRNA for 72 h) were lysed in 1 ml SEM buffer 
(0.25 M sucrose, 20 mM MOPS–KOH and 1 mM EDTA–
NaOH, pH 8) with or without 20 mM N-ethylmaleimide 
(NEM). Protease inhibitor cocktail and 1 mM DTT were 
added freshly. After brief sonication (3 strokes for 5 s at 
40% amplitude), protein concentration was measured by 
Bradford assay. Two hundred micrograms of extract was 
diluted in activity assay buffer (50 mM Tris–HCl pH 7.5, 
0.1 mg/ml BSA and 10 mM DTT) and mixed with 100 ng 
SUMO-2 vinyl sulfone derivative (HA-SUMO2-VS; Bos-
ton Biochem) compound. The reaction was kept at room 
temperature for 10  min. To stop the reaction, sample 
buffer was added followed by heating at 95° for 5 min.
Immunofluorescence
HeLa cells were fixed in methanol (MeOH) at −20 °C for 
5  min, permeabilized with 0.5% Triton X-100 and pro-
cessed using standard protocols. Images were acquired 
by Leica TCS SP8 confocal microscope. An anti-SENP3 
(clone D20A10 cat no. 5591, Cell signaling) and anti-FL II 
(SC-21716, Santa Cruz Biotechnology Inc.) were used as 
primary antibodies for detecting the respective proteins. 
The following secondary antibodies were used: Alexa 
Fluor 488–donkey anti-rabbit (Invitrogen), Cy3–donkey 
anti-mouse (Invitrogen).
Additional files
Additional file 1: Fig S1. Proteome map of SENP3 derived from 
SILAC-based mass spectrometry. (a) Schematic representation of SENP3 
proteomics. Equal no. of HeLa cells (as mentioned in “Methods”) either 
unlabeled or metabolically labeled with amino acid isotope (R6K4) was 
used for IP. Control IP and SENP3 IP were mixed in a 1:1 ratio and loaded 
in a SDS-PAGE. The whole lane was cut into several small pieces and pro-
cessed for mass spec (as described in Materials and Methods section). (b) 
One representative western blot shows the enrichment of endogenous 
SENP3 in IP lane that was used for MS analysis. (c) The cytoscape map of 
SENP3 interactome was accomplished after filtering the whole protein 
group file (generated from MaxQuant analysis) through 4 tier of following 
selection criteria—(i) normalized H/L SILAC ratio cutoff was set as 2; that 
is proteins with minimum twofold enrichment compare to IgG control 
were considered. (ii) PEP score cutoff was set as (0.0001). PEP score is like 
p value that represents statistical significance of an observed peptide as 
a true one. Therefore, smaller PEP score is significant. (iii) Minimum three 
peptides were considered for any proteins and (iv) reproducibility in both 
the independent experiments. (d) Cytoscape network of SENP3 interac-
tome obtained from two independent SILAC-MS assays. Details of the 
generation of the cytoscape map are described in appendix figure S1c. (e) 
A representative MS/MS spectrum of FLII peptide that was generated by 
MaxQuant Viewer program. Fig S2. SENP3 protein network. (a) The filtered 
protein candidates (27) generated from SENP3 proteomics were entered 
into STRING database as input to check for clustering coefficient. Red 
arrow indicates the bait, SENP3. (b) Information about FLII protein–protein 
interaction was extracted from STRING database and combined together 
with SENP3 network from our experiment. Fig S3. FLII–SENP3 interaction 
is mostly in the nucleus. (a) Related to Fig. 1. HeLa cells were transfected 
with Flag-SENP3. Two days after transfection, Flag-agarose bead pull 
down was performed to check the presence of FLII in the western blot. 
(b) Subcellular fractionation of HeLa cells was performed according to the 
user protocol (subcellular protein fractionation kit, ThermoFisher Scientific, 
catalog no. 78840). Endogenous FLII was immunoprecipitated from 
cytosolic and nuclear fraction. SDS-PAGE of the immunoprecipitate was 
performed and probed for indicated antibodies. (c) Subcellular localiza-
tion of endogenous SENP3 and FLII was studied by immunofluorescence 
using primary antibodies detecting the respective proteins. Fig S4. FLII 
interaction with RbBP5. (a) Related to Fig. 3. Endogenous FLII was immu-
noprecipitated from HeLa cells, and blot was probed against indicated 
antibodies. (b) Related to Fig. 3. Endogenous SENP3 was immunopre-
cipitated from HeLa cells, and blot was checked for indicated antibodies. 
(c) Related to Fig. 3. Endogenous WDR5 was immunoprecipitated, and 
blot was probed against indicated antibodies. (d) Same as Fig. 1d except 
RbBP5 construct was used for in vitro transcription/translation. (e) Same 
as additional file 1, Fig S3a, except Flag-tagged FLII constructs were 
used to check the interaction of various FLII domains (as indicated in the 
figure) with RbBP5. Fig S5. SENP3 is not involved in ERα and FLII does 
not influence SENP3 catalytic activity. (a) Post-transfection (control, SENP3 
and FLII siRNA), MCF7 cells were cultured for 3 days in phenol red-free 
DMEM medium supplemented with 5% charcoal-dextran-stripped fetal 
bovine serum. Cells were then treated overnight with 100 nM estradiol 
(E2) before RNA extraction. Data represent the average of triplicates from 
two biological experiments ± SEM. (b) 72 h after siRNA treatment directed 
against FLII, cell lysate was prepared in the presence or absence of NEM in 
the lysis buffer. Equal amount of protein (200μg) of protein from control 
and FLII siRNA cell lysate was mixed with SUMO2-VS [69] substrate at 
room temperature for 10 min. The SDS-PAGE was probed by using SENP3 
and a loading control tubulin antibody. The asterisk mark represents slow-
migrating catalytic active SENP3 form appeared as a result of conjugation 
between the substrate and SENP3. Right panel shows FLII knockdown effi-
ciency. (c) Same as in (a), except anti-HA antibody (that detects SUMO2-VS 
substrate) was used. Fig S6. FLII influences MLL1/2 complex assembly on 
DLX3 gene. (a) Same as Fig. 4b except 5μg of flag-FLII plasmid was trans-
fected to HeLa cells. 48 h. post-transfection cells were fixed and processed 
for ChIP using rabbit flag antibody. Data represent average of at least two 
biological experiments performed in duplicate. (b) Related to Fig. 4B. HeLa 
cell lysate was probed with indicated antibodies to monitor the depletion 
of FLII and SENP3. (C) Same as Fig. 4e, but DLX3.2 primer was used in 
qPCR (n = 3, T test, *p < 0.05; **p < 0.01; ***p < 0.001, n.s. not significant). 
(d) Same as Fig. 4e, except anti-MLL1 and anti-MLL2 antibodies were 
used for ChIP. DLX3.1 primer was used for qPCR. (e) Same as in d, except 
DLX3.2 primer was used for qPCR. Fig S7. Expression of MLL1/2 complex 
subunits is unperturbed upon FLII depletion. (a, b) To check the effect of 
FLII knockdown on MLL1/2 complex subunit protein stability, cell lysates 
from control and FLII siRNA were probed in western blot for the indicated 
antibodies. (c) Same as Fig. 4e except HOXC8 promoter primer was used 
(n = 3, n.s. not significant). (d, e) Related to Fig. 4f and g except HOXC8 
promoter primer was used. (f ) HeLa cells were transfected with FLII siRNA 
for 72 h followed by endogenous SENP3 and RbBP5 immunoprecipita-
tion. Blot was probed with indicated antibodies. (g) Same as (f ) but SENP3 
siRNA was performed and RbBP5 antibody was used for immunoprecipi-
tation. Fig S8. FLII is required for osteogenic differentiation. (a) Expression 
of RUNX2 and ALP mRNA was determined by RT-qPCR in control or DFCs 
depleted from FLII. Values (normalized for GAPDH expression) represent 
the mean of three experiments ± SEM. (b) The status of mineral deposi-
tion in DFC was measured by alizarin stain. Cells were transfected with 
two different FLII siRNA and grown in ODM culture for 5 weeks.
Additional file 2: Table S1. Table shows the detail of proteins that 
passed the filtering criteria of Fig S1.
Additional file 3. Supplementary materials and methods.
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